Fig. 6

miR-511-5p/VEGFA axis is essential for LINC00173.v1-induced tumorigenesis in vivo. a Images of the representative excised tumors from the indicated mice at 42 days after injection. b Average weight of excised tumors from the indicated mice (n = 6). Each bar represents the median values ± quartile values. P value was determined by one-way ANOVA test. c Tumor volumes were measured every 7 days. Each bar represents the median values ±quartile values. P value was determined by ANOVA test in final measurement. d Representative sections and CD31⁺ lymphatic or blood vessel (LBV) in tumor tissues from the indicated mice groups (n = 6) with bevacizumab treatment, agomir-511-5p treatment and the mutant LINC00173.v1-overexpressing NCI-H1975 cells (Left panel). Density of CD31⁺ lymphatic or blood vessel (LBV) in tumor tissues from the indicated mice groups (Right panel). Each bar represents the median values ± quartile values. P value was determined by one-way ANOVA test. Scale bars of 100× magnification, 200 μm and 400× magnification, 50 μm. e Representative lung nodules (red arrow), lung H&E section and tumor cells in lung sections of therapeutic efficacy of bevacizumab and LINC00173.v1 antisense oligonucleotide (ASO) from the indicated mice groups treated with cisplatin. PBS, bevacizumab and LINC00173.v1 ASO were injected intraperitoneally once weekly for consecutive 4 weeks respectively after 1 week of cell inoculation. Scale bars, 200 μm. f Tumor cell number per mm² in lung H&E section from the indicated mice groups after 8 weeks of tail veins injection. Each bar represents the median values ± quartile values. P value was determined by one-way ANOVA test. g Kaplan–Meier analysis of the effect of PBS, bevacizumab and LINC00173.v1 ASO on cumulative survival in the indicated mice groups (n = 8). P value was determined by Log-rank test